Global Vancomycin Market to Reach $555.5 Million by 2030
The global market for Vancomycin estimated at US$477.3 Million in the year 2022, is projected to reach a revised size of US$555.5 Million by 2030, growing at a CAGR of 1.9% over the analysis period 2022-2030. Lung Infection, one of the segments analyzed in the report, is projected to record 3.4% CAGR and reach US$201.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sepsis segment is readjusted to a revised 2.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $130 Million, While China is Forecast to Grow at 6.3% CAGR
The Vancomycin market in the U.S. is estimated at US$130 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$130.4 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -1.1% and 0.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 0% CAGR.Select Competitors (Total 12 Featured) -
- Alchemia Limited
- Alvogen
- Aphios Corporation
- Cellceutix Corporation
- CJ CheilJedang
- Eli Lilly and Company
- Enanta Pharmaceuticals
- Helix BioMedix
- LegoChem Biosciences
- Lytix Biopharma
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Vancomycin - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Vancomycin Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Vancomycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for Vancomycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for Vancomycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Lung Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for Lung Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for Lung Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Sepsis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for Sepsis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for Sepsis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Colitis & Intestinal Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Colitis & Intestinal Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Colitis & Intestinal Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Skin Soft Tissue Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Skin Soft Tissue Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Skin Soft Tissue Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
UNITED STATES
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 22: USA 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
CANADA
- Table 23: Canada Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: Canada Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 25: Canada 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
JAPAN
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 26: Japan Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Japan Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: Japan 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
CHINA
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 29: China Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: China Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: China 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
EUROPE
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 32: Europe Recent Past, Current & Future Analysis for Vancomycin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 33: Europe Historic Review for Vancomycin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: Europe 16-Year Perspective for Vancomycin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 35: Europe Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: Europe Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: Europe 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
FRANCE
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 38: France Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: France Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: France 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
GERMANY
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 41: Germany Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: Germany Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: Germany 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
ITALY
- Table 44: Italy Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: Italy Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: Italy 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 47: UK Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 48: UK Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: UK 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
SPAIN
- Table 50: Spain Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: Spain Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: Spain 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
RUSSIA
- Table 53: Russia Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: Russia Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: Russia 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 56: Rest of Europe Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: Rest of Europe Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 58: Rest of Europe 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Vancomycin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 60: Asia-Pacific Historic Review for Vancomycin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 61: Asia-Pacific 16-Year Perspective for Vancomycin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Asia-Pacific Historic Review for Vancomycin by Application - Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 64: Asia-Pacific 16-Year Perspective for Vancomycin by Application - Percentage Breakdown of Value Sales for Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue Infection and Other Applications for the Years 2014, 2023 & 2030
AUSTRALIA
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alchemia Limited
- Alvogen
- Aphios Corporation
- Cellceutix Corporation
- CJ CheilJedang
- Eli Lilly and Company
- Enanta Pharmaceuticals
- Helix BioMedix
- LegoChem Biosciences
- Lytix Biopharma
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 78 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 477.3 Million |
Forecasted Market Value ( USD | $ 555.5 Million |
Compound Annual Growth Rate | 1.9% |
Regions Covered | Global |